デフォルト表紙
市場調査レポート
商品コード
992187

遺伝子治療細胞培地市場:培地タイプ別、ウイルスベクタータイプ別、エンドユーザー別:世界の機会分析と業界予測(2020~2027年)

Gene Therapy Cell Culture Media Market by Media Type, Viral Vectors Type, and End User : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版日: | 発行: Allied Market Research | ページ情報: 英文 262 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.86円
遺伝子治療細胞培地市場:培地タイプ別、ウイルスベクタータイプ別、エンドユーザー別:世界の機会分析と業界予測(2020~2027年)
出版日: 2021年01月12日
発行: Allied Market Research
ページ情報: 英文 262 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の遺伝子治療細胞培地の市場規模は2019年に1億2,260万米ドルとなりました。

同市場は、2020年から2027年にかけて10.6%のCAGRで拡大し、2027年までに2億7,896万米ドルに達すると予測されています。

遺伝子治療細胞培地は、健康な細胞周期を調節するための十分なエネルギーを提供する重要な栄養素で構成されています。さらに、ウシ血清、動物由来の栄養素、およびEGF、FGF、IGF、PDGFなどの増殖因子が含まれています。世界中で研究開発活動が急増していることは、遺伝子治療細胞培地の主要な成長要因です。さまざまな製薬会社やバイオテクノロジー企業が遺伝子治療の研究開発に多額の投資を行っています。培地は、微生物および幹細胞、哺乳類、その他の細胞株などの他の細胞タイプの増殖、繁殖、維持、および保存のために実験室および調査環境で提供される栄養増殖物質です。さまざまな細胞培養物が培養環境で生存し成長するために、さまざまな培地が市場で入手可能です。

ウイルスベクターには、遺伝子を宿主細胞に導入するためのベクターとして使用できるすべてのウイルスが含まれます。これらのベクターはさらに、レトロウイルス、レンチウイルス、アデノウイルス、アデノ随伴ウイルス、単純ヘルペスウイルス、ポックスウイルス、ワクシニアウイルスなどに分類されます。レトロウイルスまたはアデノウイルスを利用して目的の遺伝子を送達する多くの遺伝子治療臨床試験が実施されてきました。これらのウイルスは、認識できる細胞に遺伝子を移して感染するメカニズムが異なり、細胞のDNAが恒久的または一時的に変化します。

市場の成長は、研究開発投資の増加や遺伝子治療に関する意識の高まりなどによって推進されています。ただし、熟練した専門家の不足、遺伝子治療に関連するコストの高さ、および培地に関連する倫理的および科学的懸念が市場の成長を妨げています。さらに、新興経済国の未開拓の可能性は、予測期間中に遺伝子治療細胞培養市場の成長の機会を提供することが期待されます。

当レポートでは、遺伝子治療細胞培地市場について調査し、市場の概要とともに、培地タイプ別、ウイルスベクタータイプ別、びエンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
    • 主な成功戦略
  • トッププレーヤーのポジショニング
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
      • 研究開発投資の増加
      • 遺伝子治療に関する意識の高まり
      • 遺伝子治療に関連する進歩の増加
      • 癌の有病率上昇
    • 抑制要因
      • 熟練した専門家の不足
      • 遺伝子治療に関連するコストの高さ
      • 培地に関連する倫理的および科学的懸念
    • 市場機会
      • 新興経済国の未開拓の可能性
  • 遺伝子治療細胞培地市場におけるCOVID-19の影響分析

第4章 遺伝子治療細胞培地市場

  • 概要
    • 市場規模と予測
  • 血清含有培地
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 無血清培地
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 幹細胞培地
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 特別培地
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 化学的に定義された培地
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 溶原性ブロス
    • 市場規模と予測:地域別
    • 市場分析:国別
  • カスタム培地
    • 市場規模と予測:地域別
    • 市場分析:国別
  • その他の培地
    • 市場規模と予測:地域別
    • 市場分析:国別

第5章 遺伝子治療細胞培地市場

  • 概要
    • 市場規模と予測
  • レトロウイルス
    • 市場規模と予測:地域別
    • 市場分析:国別
  • レンチウイルス
    • 市場規模と予測:地域別
    • 市場分析:国別
  • アデノウイルス
    • 市場規模と予測:地域別
    • 市場分析:国別
  • アデノ随伴ウイルス
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 単純ヘルペスウイルス
    • 市場規模と予測:地域別
    • 市場分析:国別
  • ポックスウイルス
    • 市場規模と予測:地域別
    • 市場分析:国別
  • ワクシニアウイルス
    • 市場規模と予測:地域別
    • 市場分析:国別
  • その他
    • 市場規模と予測:地域別
    • 市場分析:国別

第6章 遺伝子治療細胞培地市場:エンドユーザー別

  • 概要
    • 市場規模と予測
  • 医薬品およびバイオテクノロジー業界
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 研究機関
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 学術機関
    • 市場規模と予測:地域別
    • 市場分析:国別
  • その他
    • 市場規模と予測:地域別
    • 市場分析:国別

第7章 遺伝子治療細胞培地市場:地域別

  • 概要
    • 市場規模と予測
  • 北米
    • 主要な市場動向と機会
    • 北米の細胞培養市場:国別
      • 米国の遺伝子治療細胞培地市場:培地タイプ別
      • 米国の遺伝子治療細胞培地市場:ウイルスベクタータイプ別
      • 米国の遺伝子治療細胞培地市場:エンドユーザー別
      • カナダの遺伝子治療細胞培地市場:培地タイプ別
      • カナダの遺伝子治療細胞培地市場:ウイルス別
      • カナダの遺伝子治療細胞培地市場:エンドユーザー別
      • メキシコの遺伝子治療細胞培地市場:培地タイプ別
      • メキシコの遺伝子治療細胞培地市場:ウイルスベクタータイプ別
      • メキシコの遺伝子治療細胞培地市場:エンドユーザー別
    • 北米の遺伝子治療細胞培地市場:培地タイプ別
    • 北米の遺伝子治療細胞培地市場:ウイルス別
    • 北米の遺伝子治療細胞培地市場:エンドユーザー別
  • 欧州
    • 主要な市場動向と機会
    • 欧州の遺伝子治療細胞培地市場:国別
      • ドイツの遺伝子治療細胞培地市場:培地タイプ別
      • ドイツの遺伝子治療細胞培地市場:ウイルス別
      • ドイツの遺伝子治療細胞培地市場:エンドユーザー別
      • フランスの遺伝子治療細胞培地市場:培地タイプ別
      • フランスの遺伝子治療細胞培地市場:ウイルスベクタータイプ別
      • フランスの遺伝子治療細胞培地市場:エンドユーザー別
      • 英国の遺伝子治療細胞培地市場:培地タイプ別
      • 英国の遺伝子治療細胞培地市場:ウイルスベクタータイプ別
      • 英国の遺伝子治療細胞培地市場:エンドユーザー別
      • イタリアの遺伝子治療細胞培地市場:培地タイプ別
      • イタリアの遺伝子治療細胞培地市場:ウイルスベクタータイプ別
      • イタリアの遺伝子治療細胞培地市場:エンドユーザー別
      • スペインの遺伝子治療細胞培地市場:培地タイプ別
      • スペインの遺伝子治療細胞培地市場:ウイルスベクタータイプ別
      • スペインの遺伝子治療細胞培地市場:エンドユーザー別
      • その他欧州の遺伝子治療細胞培地市場
      • その他欧州の遺伝子治療細胞培地市場
      • その他欧州の遺伝子治療細胞培地市場:エンドユーザー別
    • 欧州の遺伝子治療細胞培地市場:培地タイプ別
    • 欧州の遺伝子治療細胞培地市場:ウイルスベクタータイプ別
    • 欧州の遺伝子治療細胞培地市場:エンドユーザー別
  • アジア太平洋地域
    • 主要な市場動向と機会
    • アジア太平洋の遺伝子治療細胞培地市場:国別
      • 中国の遺伝子治療細胞培地市場:培地タイプ別
      • 中国の遺伝子治療細胞培地市場:ウイルスベクタータイプ別
      • 中国の遺伝子治療細胞培地市場:エンドユーザー別
      • 日本の遺伝子治療細胞培地市場:培地タイプ別
      • 日本の遺伝子治療細胞培地市場:ウイルスベクタータイプ別
      • 日本の遺伝子治療細胞培地市場:エンドユーザー別
      • オーストラリアの遺伝子治療細胞培地市場:培地タイプ別
      • オーストラリアの遺伝子治療細胞培地市場:ウイルス別
      • オーストラリアの遺伝子治療細胞培地市場:エンドユーザー別
      • インドの遺伝子治療細胞培地市場:培地タイプ別
      • インドの遺伝子治療細胞培地市場:ウイルスベクタータイプ別
      • インドの遺伝子治療細胞培地市場:エンドユーザー別
      • 韓国の遺伝子治療細胞培地市場:培地タイプ別
      • 韓国の遺伝子治療細胞培地市場:ウイルス別
      • 韓国の遺伝子治療細胞培地市場:エンドユーザー別
      • その他アジア太平洋地域の遺伝子治療細胞培地市場
      • その他アジア太平洋地域の遺伝子治療細胞培地市場
      • その他の遺伝子治療細胞培地市場
    • アジア太平洋の遺伝子治療細胞培地市場:培地タイプ別
    • アジア太平洋の遺伝子治療細胞培地市場
    • アジア太平洋の遺伝子治療細胞培地市場:エンドユーザー別
  • LAMEA
    • 主要な市場動向と機会
    • LAMEA遺伝子治療細胞培地市場:国別
      • ブラジルの遺伝子治療細胞培地市場:培地タイプ別
      • ブラジルの遺伝子治療細胞培地市場:ウイルスベクタータイプ別
    • ブラジルの遺伝子治療細胞培地市場:エンドユーザー別
      • サウジアラビア遺伝子治療細胞培地市場
      • サウジアラビア遺伝子治療細胞培地市場
    • サウジアラビア遺伝子治療細胞培地市場:エンドユーザー別
      • 南アフリカの遺伝子治療細胞培地市場:培地タイプ別
      • 南アフリカの遺伝子治療細胞培地市場:ウイルス別
    • 南アフリカの遺伝子治療細胞培地市場:エンドユーザー別
      • その他のLAMEA遺伝子治療細胞培地市場
      • その他のLAMEA遺伝子治療細胞培地市場
    • その他のLAMEA遺伝子治療細胞培地市場:エンドユーザー別
    • LAMEA遺伝子治療細胞培地市場:培地タイプ別
    • LAMEA遺伝子治療細胞培地市場:ウイルスベクタータイプ別
    • LAMEA遺伝子治療細胞培地市場:エンドユーザー別

第8章 企業プロファイル

  • BIO-TECHNE CORPORATION
  • DANAHER CORPORATION (CYTIVA)
  • FUJIFILM HOLDINGS CORPORATION (FUJIFILM IRVINE SCIENTIFIC)
  • HIMEDIA LABORATORIES
  • LONZA GROUP LTD
  • MERCK KGAA
  • NOVARTIS INTERNATIONAL AG
  • SARTORIUS AG
  • THERMO FISHER SCIENTIFIC, INC.
  • TAKARA HOLDINGS INC. (TAKARA BIO INC.)
図表

LIST OF TABLES

  • TABLE 01.GENE THERPAY CELL CULTURE MEDIA MARKET BY MEDIA TYPE 2019-2027, ($MILLION)
  • TABLE 02.GENE THERAPY CELL CULTURE MEDIA MARKET FOR SERUM CONTAINING MEDIA, BY REGION

2019-2027($MILLION)

  • TABLE 03.GENE THERAPY CELL CULTURE MEDIA MARKET FOR SERUM FREE MEDIA, BY REGION

2019-2027($MILLION)

  • TABLE 04.GENE THERAPY CELL CULTURE MEDIA MARKET FOR STEM CELL MEDIA, BY REGION

2019-2027($MILLION)

  • TABLE 05.GENE THERAPY CELL CULTURE MEDIA MARKET FOR SPECIALTY MEDIA, BY REGION

2019-2027($MILLION)

  • TABLE 06.GENE THERAPY CELL CULTURE MEDIA MARKET FOR CHEMICALLY DEFINED MEDIA,

BY REGION 2019-2027($MILLION)

  • TABLE 07.GENE THERAPY CELL CULTURE MEDIA MARKET FOR LYSOGENY BROTH, BY REGION
  • 2019-2027($MILLION)
  • TABLE 08.GENE THERAPY CELL CULTURE MEDIA MARKET FOR CUSTOM MEDIA, BY REGION
  • 2019-2027($MILLION)
  • TABLE 09.GENE THERAPY CELL CULTURE MEDIA MARKET FOR OTHER MEDIA, BY REGION
  • 2019-2027($MILLION)
  • TABLE 10.GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
  • TABLE 11.GENE THERAPY CELL CULTURE MEDIA MARKET FOR RETROVIRUSES, BY REGION
  • 2019-2027($MILLION)
  • TABLE 12.GENE THERAPY CELL CULTURE MEDIA MARKET FOR LENTIVIRUSES, BY REGION
  • 2019-2027($MILLION)
  • TABLE 13.GENE THERAPY CELL CULTURE MEDIA MARKET FOR ADENOVIRUSES, BY REGION
  • 2019-2027($MILLION)
  • TABLE 14.GENE THERAPY CELL CULTURE MEDIA MARKET FOR ADENO ASSOCIATED VIRUS, BY REGION
  • 2019-2027($MILLION)
  • TABLE 15.GENE THERAPY CELL CULTURE MEDIA MARKET FOR HERPES SIMPLEX VIRUS, BY REGION
  • 2019-2027($MILLION)
  • TABLE 16.GENE THERAPY CELL CULTURE MEDIA MARKET FOR POXVIRUS, BY REGION 2019-2027($MILLION)
  • TABLE 17.GENE THERAPY CELL CULTURE MEDIA MARKET FOR VACCINIA VIRUS, BY REGION
  • 2019-2027($MILLION)
  • TABLE 18.GENE THERAPY CELL CULTURE MEDIA MARKET FOR OTHERS, BY REGION 2019-2027($MILLION)
  • TABLE 19.GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 20.GENE THERAPY CELL CULTURE MEDIA MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY
  • INDUSTRIES, BY REGION 2019-2027($MILLION)
  • TABLE 21.GENE THERAPY CELL CULTURE MEDIA MARKET FOR RESEARCH LABORATORIES, BY REGION
  • 2019-2027 ($MILLION)
  • TABLE 22.GENE THERAPY CELL CULTURE MEDIA MARKET FOR ACADEMIC INSTITUTIONS, BY REGION
  • 2019-2027 ($MILLION)
  • TABLE 23.GENE THERAPY CELL CULTURE MEDIA MARKET FOR OTHERS, BY REGION 2019-2027 ($MILLION)
  • TABLE 24.GENE THERAPY CELL CULTURE MEDIA MARKET REVENUE, BY REGION, 2019-2027($MILLION)
  • TABLE 25.NORTH AMERICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY,
  • 2019-2027($MILLION)
  • TABLE 26.U.S. GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 27.U.S. GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
  • TABLE 28.U.S. GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 29.CANADA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 30.CANADA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 31.CANADA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 32.MEXICO GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 33.MEXICO GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 34.MEXICO GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 35.NORTH AMERICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
  • 2019-2027($MILLION)
  • TABLE 36.NORTH AMERICA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 37.NORTH AMERICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
  • 2019-2027($MILLION)
  • TABLE 38.EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY, 2019-2027($MILLION)
  • TABLE 39.GERMANY GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 40.GERMANY GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 41.GERMANY GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 42.FRANCE GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 43.FRANCE GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 44.FRANCE GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 45.UK GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 46.UK GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
  • TABLE 47.UK GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 48.ITALY GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 49.ITALY GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
  • TABLE 50.ITALY GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 51.SPAIN GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 52.SPAIN GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 53.SPAIN GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 54.REST OF EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
  • 2019-2027($MILLION)
  • TABLE 55.REST OF EUROPE GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 56.REST OF EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
  • 2019-2027($MILLION)
  • TABLE 57.EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 58.EUROPE GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 59.EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 60.ASIA-PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY, 2019-2027($MILLION)
  • TABLE 61.CHINA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 62.CHINA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 63.CHINA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 64.JAPAN GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 65.JAPAN GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 66.JAPAN GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 67.AUSTRALIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 68.AUSTRALIA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 69.AUSTRALIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 70.INDIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 71.INDIA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
  • TABLE 72.INDIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 73.SOUTH KOREA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
  • 2019-2027($MILLION)
  • TABLE 74.SOUTH KOREA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 75.SOUTH KOREA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 76.REST OF ASIA-PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
  • 2019-2027($MILLION)
  • TABLE 77.REST OF ASIA-PACIFIC GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 78.REST OF ASIA PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
  • 2019-2027($MILLION)
  • TABLE 79.ASIA-PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
  • 2019-2027($MILLION)
  • TABLE 80.ASIA PACIFIC GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 81.ASIA- PACIFC GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 82.LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY, 2019-2027($MILLION)
  • TABLE 83.BRAZIL GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 84.BRAZIL GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 85.BRAZIL GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 86.SAUDI ARABIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
  • 2019-2027($MILLION)
  • TABLE 87.SAUDI ARABIA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 88.SAUDI ARABIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 89.SOUTH AFRICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
  • 2019-2027($MILLION)
  • TABLE 90.SOUTH AFRICA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 91.SOUTH AFRICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
  • 2019-2027($MILLION)
  • TABLE 92.REST OF LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
  • 2019-2027($MILLION)
  • TABLE 93.REST OF LAMEA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 94.REST OF LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
  • 2019-2027($MILLION)20
  • TABLE 95.LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019-2027($MILLION)
  • TABLE 96.ASIA PACIFIC GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
  • 2019-2027, ($MILLION)
  • TABLE 97.LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027($MILLION)
  • TABLE 98.BIO-TECHNE: COMPANY SNAPSHOT
  • TABLE 99.OPERATING BUSINESS SEGMENT
  • TABLE 100.BIO-TECHNE: PRODUCT PORTFOLIO
  • TABLE 101.DANAHER: COMPANY SNAPSHOT
  • TABLE 102.DANAHER: OPERATING SEGMENT
  • TABLE 103.GE HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 104.FUJIFILM: COMPANY SNAPSHOT
  • TABLE 105.FUJIFILM: OPERATING SEGMENTS
  • TABLE 106.FUJIFILM: PRODUCT PORTFOLIO
  • TABLE 107.HIMEDIA: COMPANY SNAPSHOT
  • TABLE 108.HIMEDIA:OPERATING PRODUCT SEGMENT
  • TABLE 109.HIMEDIA: PRODUCT PORTFOLIO
  • TABLE 110.LONZA: COMPANY SNAPSHOT
  • TABLE 111.PRODUCT PORTFOLIO
  • TABLE 112.LONZA: PRODUCT PORTFOLIO
  • TABLE 113.SARTORIUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114.MERCK: COMPANY SNAPSHOT
  • TABLE 115.MERCK: OPERATING SEGMENTS
  • TABLE 116.MERCK: PRODUCT PORTFOLIO
  • TABLE 117.SARTORIUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 119.NOVARTIS: OPERATING SEGMENTS
  • TABLE 120.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 121.SARTORIUS: COMPANY SNAPSHOT
  • TABLE 122.SARTORIUS: OPERATING BUSINESS SEGMENTS
  • TABLE 123.SARTORIUS: PRODUCT PORTFOLIO
  • TABLE 124.THERMO FISHER: COMPANY SNAPSHOT
  • TABLE 125.THERMO FISHER.: OPERATING SEGMENTS
  • TABLE 126.THERMO FISHER.: PRODUCT PORTFOLIO
  • TABLE 127.THERMO FISHER SCIENTIFIC : KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128.TAKARA GROUP: COMPANY SNAPSHOT
  • TABLE 129.TAKARA GROUP: OPERATING SEGMENTS
  • TABLE 130.TAKARA GROUP: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.GENE THERAPY CELL CULTURE MEDIA MARKETSEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020*
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020*
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020*
  • FIGURE 06.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 07.LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 08.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 09.LOW THREAT OF SUBSTITUTION
  • FIGURE 10.MODERATE COMPETITIVE RIVALRY
  • FIGURE 11.DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 12.GENE THERAPY PIPELINE VOLUME, PRECLINICAL THROUGH PRE-REGISTRATION PHASE, 1995-2018
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

SERUM CONTAINING MEDIA, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

SERUM FREE MEDIA, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

STEM CELL MEDIA, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

SPECIALTY MEDIA, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

CHEMICALLY DEFINED MEDIA, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

LYSOGENY BROTH, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

CUSTOM MEDIA, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

OTHER MEDIA, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

RETROVIRUSES, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

LENTIVIRUSES, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

ADENOVIRUSES, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

ADENO ASSOCIATED VIRUS, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

HERPES SIMPLEX VIRUS, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

POXVIRUS, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

VACCINIA VIRUS, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 28.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

OTHERS, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 29.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRIES, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR

RESEARCH LABORATORIES, BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 31.COMPARATIVE SHARE ANALYSIS OF CELL CULTURE MARKET FOR ACADEMIC INSTITUTIONS,

BY COUNTRY, 2019 & 2027 (%)

  • FIGURE 32.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
  • OTHERS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 33.BIO-TECHNE: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 34.BIO-TECHNE: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 35.BIO-TECHNE: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 36.DANAHER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 37.DANAHER: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 38.DANAHER: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 39.FUJIFILM: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 40.FUJIFILM: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 41.LONZA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 42.LONZA: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 43.MERCK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 44.MERCK: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 45.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 46.NOVARTIS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 47.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 48.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 49.SARTORIUS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 50.SARTORIUS: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 51.SARTORIUS: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 52.THERMO FISHER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 53.THERMO FISHER: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 54.THERMO FISHER: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 55.TAKARA GROUP: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 56.TAKARA GROUP: REVENUE SHARE, BY SEGMENT, 2019 (%)
目次
Product Code: A09065

The global gene therapy cell culture media market accounted for $122.60 million in 2019, and is expected to reach $278.96 million by 2027, registering a CAGR of 10.6% from 2020 to 2027.

Gene therapy cell culture media consists of important nutrients that provide ample energy to regulate healthy cell cycle. Moreover, it contains bovine serum, animal-derived nutrients, and growth factors like EGF, FGF, IGF, and PDGF. A surge in R&D activities worldwide are prime factor for the growth of the gene therapy cell culture media. Various pharmaceutical and biotechnology companies are heavily investing in R&D of gene therapy. Culture media are nutrient growth substances provided in laboratory and research settings for growth, proliferation, maintenance, and storage of microorganisms and other cell types such as stem cells, mammalian, and other cell lines. Different culture media are available in the market for various cell cultures to survive and grow in their incubation environment.

Viral vectors include all viruses that can be used as vectors for the transfer of genes into a host cell. These vectors are further categorized into retroviruses, lentiviruses, adenoviruses, adeno-associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Many gene therapy clinical trials have been conducted that make use of retroviruses or adenoviruses to deliver the desired gene. These viruses vary in regards with the mechanism of transferring the genes to those cells which they can recognize and then they infect, which leads to change in the cell's DNA permanently or temporarily.

The market growth is driven due to factors such as rise in R&D investments, and growth in awareness regarding gene therapy. However, dearth of skilled professionals, high costs associated with gene therapies, and ethical & scientific concerns associated with culture media hamper the market growth. Moreover, untapped potential of the emerging economies is expected to offer opportunities for gene therapy cell culture market growth during the forecast period.

The segment is divided into media type, viral vectors type, end user, and region. By media type is further divided into serum containing media, serum free media, stem cell media, specialty media, chemically defined media, lysogeny broth, custom media, and others. In addition, the viral vectors are divided into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Further, by end user, the market is classified into biotechnology & pharmaceutical industry, academic institute, research laboratory, and others. By region, the gene therapy cell culture media market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The gene therapy cell culture media market provides extensive competitive analysis and profiles of key market players, such as Fujifilm Holdings Corporation, HiMedia Laboratories Pvt., Ltd, Lonza Group Ltd, Sartorius AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Takara Holdings Inc., Novartis International AG, and Bio-Techne Corporation.

KEY BENEFITS FOR STAKEHOLDERS

This report entails a detailed quantitative analysis of the current market trends from 2019 to 2027 to identify the prevailing opportunities.

The gene therapy cell culture media market size and estimations are based on comprehensive analysis of the key developments in the industry.

In-depth analysis based on region assists to understand the regional market and the strategic business planning.

The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Media Type

  • Serum-containing Media
  • Serum-free Media
  • Stem Cell Media
  • Specialty Media
  • Chemically Defined Media
  • Lysogeny Broth
  • Custom Media
  • Others

By Viral Vectors Type

  • Retroviruses
  • Lentiviruses
  • Adenoviruses
  • Adeno-associated Virus
  • Herpes Simplex Virus
  • Poxvirus
  • Vaccinia Virus
  • Others

By End-User

  • Biotechnology & Pharmaceutical Industry
  • Academic Institute
  • Research Laboratory
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Fujifilm Holdings Corporation
  • HiMedia Laboratories Pvt., Ltd
  • Lonza Group Ltd
  • Sartorius AG (S
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Takara Holdings Inc.
  • Novartis International AG
  • Bio-Techne Corporation

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
    • 2.1.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Top player positioning
  • 3.4.Porter's five forces analysis
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Rise in R&D investments
      • 3.5.1.2.Growth in awareness regarding gene therapy
      • 3.5.1.3.Increase in advancements associated gene therapy
      • 3.5.1.4.Increase in prevalence of cancer
    • 3.5.2.Restraints
      • 3.5.2.1.Dearth of skilled professionals
      • 3.5.2.2.High cost associated with gene therapies
      • 3.5.2.3.Ethical & scientific concerns associated with culture media
    • 3.5.3.Opportunity
      • 3.5.3.1.Untapped potential of the emerging economies
  • 3.6.Impact Analysis of COVID-19 on Gene Therapy Cell Culture Media Market

CHAPTER 4:GENE THERAPY CELL CULTURE MEDIA MARKET, BY

MEDIA TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Serum-containing media
    • 4.2.1.Market size and forecast, by region
    • 4.2.2.Market analysis by country
  • 4.3.Serum-free media
    • 4.3.1.Market size and forecast, by region
    • 4.3.2.Market analysis by country
  • 4.4.Stem cell media
    • 4.4.1.Market size and forecast, by region
    • 4.4.2.Market analysis by country
  • 4.5.Specialty media
    • 4.5.1.Market size and forecast, by region
    • 4.5.2.Market analysis by country
  • 4.6.Chemically defined media
    • 4.6.1.Market size and forecast, by region
    • 4.6.2.Market analysis by country
  • 4.7.Lysogeny broth
    • 4.7.1.Market size and forecast, by region
    • 4.7.2.Market analysis by country
  • 4.8.Custom media
    • 4.8.1.Market size and forecast, by region
    • 4.8.2.Market analysis by country
  • 4.9.Other media
    • 4.9.1.Market size and forecast, by region
    • 4.9.2.Market analysis by country

CHAPTER 5:GENE THERAPY CELL CULTURE MEDIA MARKET, BY

VIRAL VECTORS TYPE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Retroviruses
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis by country
  • 5.3.Lentiviruses
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis by country
  • 5.4.Adenoviruses
    • 5.4.1.Market size and forecast, by region
    • 5.4.2.Market analysis by country
  • 5.5.Adeno associated virus
    • 5.5.1.Market size and forecast, by region
    • 5.5.2.Market analysis by country
  • 5.6.Herpes simplex virus
    • 5.6.1.Market size and forecast, by region
    • 5.6.2.Market analysis by country
  • 5.7.Poxvirus
    • 5.7.1.Market size and forecast, by region
    • 5.7.2.Market analysis by country
  • 5.8.Vaccinia virus
    • 5.8.1.Market size and forecast, by region
    • 5.8.2.Market analysis by country
  • 5.9.Others
    • 5.9.1.Market size and forecast, by region
    • 5.9.2.Market analysis by country

CHAPTER 6:GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Pharmaceutical & biotechnology Industries
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis by country
  • 6.3.Research Laboratories
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis by country
  • 6.4.Academic Institutions
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis by country
  • 6.5.Others
    • 6.5.1.Market size and forecast, by region
    • 6.5.2.Market analysis by country

CHAPTER 7:GENE THERAPY CELL CULTURE MEDIA MARKET, BY REGION

  • 7.1.OVERVIEW
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends and opportunities
    • 7.2.2.North America cell culture market, by country
      • 7.2.2.1.U.S. gene therapy cell culture media market, by media type
      • 7.2.2.2.U.S. gene therapy cell culture media market, by viral vectors type
      • 7.2.2.3.U.S. gene therapy cell culture media market, by end user
      • 7.2.2.4.Canada gene therapy cell culture media market, by media type
      • 7.2.2.5.Canada gene therapy cell culture media market, by viral

vectors type

      • 7.2.2.6.Canada gene therapy cell culture media market, by end user
      • 7.2.2.7.Mexico gene therapy cell culture media market, by media type
      • 7.2.2.8.Mexico gene therapy cell culture media market, by viral vectors type
      • 7.2.2.9.Mexico gene therapy cell culture media market, by end user
    • 7.2.3.North America gene therapy cell culture media market, by media type
    • 7.2.4.North America gene therapy cell culture media market, by viral

vectors type

    • 7.2.5.North America gene therapy cell culture media market, by end user
  • 7.3.Europe
    • 7.3.1.Key market trends and opportunities
    • 7.3.2.Europe gene therapy cell culture media market, by country
      • 7.3.2.1.Germany gene therapy cell culture media market, by media type
      • 7.3.2.2.Germany gene therapy cell culture media market, by viral

vectors type

      • 7.3.2.3.Germany gene therapy cell culture media market, by end user
      • 7.3.2.4.France gene therapy cell culture media market, by media type
      • 7.3.2.5.France gene therapy cell culture media market, by viral vectors type
      • 7.3.2.6.France gene therapy cell culture media market, by end user
      • 7.3.2.7.UK gene therapy cell culture media market, by media type
      • 7.3.2.8.UK gene therapy cell culture media market, by viral vectors type
      • 7.3.2.9.Uk gene therapy cell culture media market, by end user
      • 7.3.2.10.Italy gene therapy cell culture media market, by media type
      • 7.3.2.11.Italy gene therapy cell culture media market, by viral vectors type
      • 7.3.2.12.Italy gene therapy cell culture media market, by end user
      • 7.3.2.13.Spain gene therapy cell culture media market, by media type
      • 7.3.2.14.Spain gene therapy cell culture media market, by viral vectors type
      • 7.3.2.15.Spain gene therapy cell culture media market, by end user
      • 7.3.2.16.Rest of Europe gene therapy cell culture media market,

by media type

      • 7.3.2.17.Rest of Europe gene therapy cell culture media market,

by viral vectors type

      • 7.3.2.18.Rest of Europe gene therapy cell culture media market, by end user
    • 7.3.3.Europe gene therapy cell culture media market, by media type
    • 7.3.4.Europe gene therapy cell culture media market, by viral vectors type
    • 7.3.5.Europe gene therapy cell culture media market, by end user
  • 7.4.Asia-Pacifi
    • 7.4.1.Key market trends and opportunities
    • 7.4.2.Asia-Pacific gene therapy cell culture media market, by country
      • 7.4.2.1.China gene therapy cell culture media market, by media type
      • 7.4.2.2.China gene therapy cell culture media market, by viral vectors type
      • 7.4.2.3.China gene therapy cell culture media market, by end user
      • 7.4.2.4.Japan gene therapy cell culture media market, by media type
      • 7.4.2.5.Japan gene therapy cell culture media market, by viral vectors type
      • 7.4.2.6.Japan gene therapy cell culture media market, by end user
      • 7.4.2.7.Australia gene therapy cell culture media market, by media type
      • 7.4.2.8.Australia gene therapy cell culture media market, by viral

vectors type

      • 7.4.2.9.Australia gene therapy cell culture media market, by end user
      • 7.4.2.10.India gene therapy cell culture media market, by media type
      • 7.4.2.11.India gene therapy cell culture media market, by viral vectors type
      • 7.4.2.12.India gene therapy cell culture media market, by end user
      • 7.4.2.13.South Korea gene therapy cell culture media market, by media type
      • 7.4.2.14.South Korea gene therapy cell culture media market, by viral

vectors type

      • 7.4.2.15.South Korea gene therapy cell culture media market, by end user
      • 7.4.2.16.Rest of Asia-Pacific gene therapy cell culture media market,

by media type

      • 7.4.2.17.Rest of Asia-Pacific gene therapy cell culture media market,

by viral vectors type

      • 7.4.2.18.Rest of Asia- Pacific gene therapy cell culture media market,

by end user

    • 7.4.3.Asia- Pacific gene therapy cell culture media market, by media type
    • 7.4.4.Asia- Pacific gene therapy cell culture media market, by

viral vectors type

    • 7.4.5.Asia- Pacific gene therapy cell culture media market, by end user
  • 7.5.LAMEA
    • 7.5.1.Key market trends and opportunities
    • 7.5.2.LAMEA gene therapy cell culture media market, by country
      • 7.5.2.1.Brazil gene therapy cell culture media market, by media type
      • 7.5.2.2.Brazil gene therapy cell culture media market, by viral vectors type
    • 7.5.3.Brazil gene therapy cell culture media market, by end user
      • 7.5.3.1.Saudi Arabia gene therapy cell culture media market,

by media type

      • 7.5.3.2.Saudi Arabia gene therapy cell culture media market, by

viral vectors type

    • 7.5.4.Saudi Arabia gene therapy cell culture media market, by end user
      • 7.5.4.1.South Africa gene therapy cell culture media market, by media type
      • 7.5.4.2.South Africa gene therapy cell culture media market, by viral

vectors type

    • 7.5.5.South Africa gene therapy cell culture media market, by end user
      • 7.5.5.1.Rest of LAMEA gene therapy cell culture media market,

by media type

      • 7.5.5.2.Rest of LAMEA gene therapy cell culture media market, by

viral vectors type

    • 7.5.6.REST OF LAMEA gene therapy cell culture media market, by end user
    • 7.5.7.LAMEA gene therapy cell culture media market, by media type
    • 7.5.8.LAMEA gene therapy cell culture media market, by viral vectors type
    • 7.5.9.LAMEA gene therapy cell culture media market, by end user

CHAPTER 8:COMPANY PROFILES

  • 8.1.BIO-TECHNE CORPORATION
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Operating product portfolio
    • 8.1.5.Business performance
  • 8.2.DANAHER CORPORATION (CYTIVA)
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
  • 8.3.FUJIFILM HOLDINGS CORPORATION (FUJIFILM IRVINE SCIENTIFIC)
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
    • 8.3.6.Key strategic moves and developments
  • 8.4.HIMEDIA LABORATORIES
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
  • 8.5.LONZA GROUP LTD
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Operating product portfolio
    • 8.5.5.Business performance
    • 8.5.6.Key strategic moves and developments
  • 8.6.MERCK KGAA
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
    • 8.6.6.Key strategic moves and developments
  • 8.7.NOVARTIS INTERNATIONAL AG
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
    • 8.7.6.Key strategic moves and developments
  • 8.8.SARTORIUS AG
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.THERMO FISHER SCIENTIFIC, INC.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
    • 8.9.6.Key strategic moves and developments
  • 8.10.TAKARA HOLDINGS INC. (TAKARA BIO INC.)
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance